AU2427588A - Recombinant avipox virus - Google Patents

Recombinant avipox virus

Info

Publication number: AU2427588A
Authority: AU; Australia
Prior art keywords: virus; antigen; vertebrate; avipox; promoter
Prior art date: 1987-08-28
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Abandoned

Application number

AU24275/88A

Other languages

English (en)

Inventor

Enzo Paoletti

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Health Research Inc

Original Assignee

Health Research Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1987-08-28

Filing date

1988-08-24

Publication date

1989-05-02

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27492413&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2427588(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1988-08-24 Application filed by Health Research Inc filed Critical Health Research Inc

1989-05-02 Publication of AU2427588A publication Critical patent/AU2427588A/en

Status Abandoned legal-status Critical Current

Links

241000700663 Avipoxvirus Species 0.000 title claims description 51
241000700605 Viruses Species 0.000 claims description 164
108090000623 proteins and genes Proteins 0.000 claims description 134
239000000427 antigen Substances 0.000 claims description 83
102000036639 antigens Human genes 0.000 claims description 83
108091007433 antigens Proteins 0.000 claims description 83
206010037742 Rabies Diseases 0.000 claims description 80
238000000034 method Methods 0.000 claims description 68
208000000666 Fowlpox Diseases 0.000 claims description 67
241000271566 Aves Species 0.000 claims description 56
206010046865 Vaccinia virus infection Diseases 0.000 claims description 51
241000251539 Vertebrata <Metazoa> Species 0.000 claims description 51
208000007089 vaccinia Diseases 0.000 claims description 51
241000700662 Fowlpox virus Species 0.000 claims description 35
241000283973 Oryctolagus cuniculus Species 0.000 claims description 33
241000700618 Vaccinia virus Species 0.000 claims description 33
241000714165 Feline leukemia virus Species 0.000 claims description 32
230000028993 immune response Effects 0.000 claims description 31
244000052769 pathogen Species 0.000 claims description 31
101710154606 Hemagglutinin Proteins 0.000 claims description 26
101710093908 Outer capsid protein VP4 Proteins 0.000 claims description 26
101710135467 Outer capsid protein sigma-1 Proteins 0.000 claims description 26
101710176177 Protein A56 Proteins 0.000 claims description 26
230000001717 pathogenic effect Effects 0.000 claims description 26
239000000185 hemagglutinin Substances 0.000 claims description 22
108010061100 Nucleoproteins Proteins 0.000 claims description 21
241000711450 Infectious bronchitis virus Species 0.000 claims description 20
102000011931 Nucleoproteins Human genes 0.000 claims description 19
239000011159 matrix material Substances 0.000 claims description 19
241000124008 Mammalia Species 0.000 claims description 15
241000714266 Bovine leukemia virus Species 0.000 claims description 14
241000700584 Simplexvirus Species 0.000 claims description 13
241000711404 Avian avulavirus 1 Species 0.000 claims description 12
241000283690 Bos taurus Species 0.000 claims description 12
241000699670 Mus sp. Species 0.000 claims description 12
230000001939 inductive effect Effects 0.000 claims description 12
230000010076 replication Effects 0.000 claims description 11
241000712461 unidentified influenza virus Species 0.000 claims description 11
108020001507 fusion proteins Proteins 0.000 claims description 8
241000178270 Canarypox virus Species 0.000 claims description 6
241000282472 Canis lupus familiaris Species 0.000 claims description 6
241000282326 Felis catus Species 0.000 claims description 6
101000678879 Homo sapiens Atypical chemokine receptor 1 Proteins 0.000 claims description 5
102000002322 Egg Proteins Human genes 0.000 claims description 4
108010000912 Egg Proteins Proteins 0.000 claims description 4
208000002979 Influenza in Birds Diseases 0.000 claims description 4
206010064097 avian influenza Diseases 0.000 claims description 4
102000037865 fusion proteins Human genes 0.000 claims description 4
210000004681 ovum Anatomy 0.000 claims description 4
241001494479 Pecora Species 0.000 claims description 3
241000713824 Rous-associated virus Species 0.000 claims description 3
102100022717 Atypical chemokine receptor 1 Human genes 0.000 claims 3
241000282887 Suidae Species 0.000 claims 1
239000013612 plasmid Substances 0.000 description 133
239000012634 fragment Substances 0.000 description 99
210000004027 cell Anatomy 0.000 description 65
108010054576 Deoxyribonuclease EcoRI Proteins 0.000 description 48
238000011081 inoculation Methods 0.000 description 46
241000287828 Gallus gallus Species 0.000 description 45
238000003780 insertion Methods 0.000 description 45
230000037431 insertion Effects 0.000 description 45
235000013330 chicken meat Nutrition 0.000 description 44
239000013598 vector Substances 0.000 description 42
108020004414 DNA Proteins 0.000 description 41
102000053602 DNA Human genes 0.000 description 41
238000010276 construction Methods 0.000 description 35
230000014509 gene expression Effects 0.000 description 34
230000006798 recombination Effects 0.000 description 34
108091034117 Oligonucleotide Proteins 0.000 description 31
238000012360 testing method Methods 0.000 description 31
238000005215 recombination Methods 0.000 description 29
241001465754 Metazoa Species 0.000 description 27
229960005486 vaccine Drugs 0.000 description 27
108091026890 Coding region Proteins 0.000 description 25
230000029087 digestion Effects 0.000 description 24
208000015181 infectious disease Diseases 0.000 description 24
210000002966 serum Anatomy 0.000 description 23
102000004169 proteins and genes Human genes 0.000 description 21
238000011144 upstream manufacturing Methods 0.000 description 19
102000004594 DNA Polymerase I Human genes 0.000 description 17
108010017826 DNA Polymerase I Proteins 0.000 description 17
108090000288 Glycoproteins Proteins 0.000 description 17
108700004025 env Genes Proteins 0.000 description 17
101150030339 env gene Proteins 0.000 description 17
238000002474 experimental method Methods 0.000 description 17
238000000338 in vitro Methods 0.000 description 17
102000003886 Glycoproteins Human genes 0.000 description 16
102000005936 beta-Galactosidase Human genes 0.000 description 15
108010005774 beta-Galactosidase Proteins 0.000 description 15
230000004044 response Effects 0.000 description 15
230000003902 lesion Effects 0.000 description 14
239000002773 nucleotide Substances 0.000 description 14
125000003729 nucleotide group Chemical group 0.000 description 14
238000012809 post-inoculation Methods 0.000 description 14
101150082239 G gene Proteins 0.000 description 13
230000036961 partial effect Effects 0.000 description 13
241000894007 species Species 0.000 description 13
238000002255 vaccination Methods 0.000 description 12
101150069452 z gene Proteins 0.000 description 12
241001135961 Amsacta moorei entomopoxvirus Species 0.000 description 11
241000588724 Escherichia coli Species 0.000 description 10
108700026244 Open Reading Frames Proteins 0.000 description 10
230000000890 antigenic effect Effects 0.000 description 10
239000002299 complementary DNA Substances 0.000 description 10
239000006166 lysate Substances 0.000 description 10
241000714233 Rous-associated virus type 1 Species 0.000 description 9
238000007918 intramuscular administration Methods 0.000 description 9
238000001556 precipitation Methods 0.000 description 9
229920002477 rna polymer Polymers 0.000 description 9
238000002965 ELISA Methods 0.000 description 8
108091028043 Nucleic acid sequence Proteins 0.000 description 8
238000010790 dilution Methods 0.000 description 8
239000012895 dilution Substances 0.000 description 8
230000002068 genetic effect Effects 0.000 description 8
238000009396 hybridization Methods 0.000 description 8
230000002458 infectious effect Effects 0.000 description 8
206010022000 influenza Diseases 0.000 description 8
238000004519 manufacturing process Methods 0.000 description 8
230000000405 serological effect Effects 0.000 description 8
101100484387 Fowlpox virus FPV127 gene Proteins 0.000 description 7
108091081024 Start codon Proteins 0.000 description 7
238000010367 cloning Methods 0.000 description 7
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 6
238000004458 analytical method Methods 0.000 description 6
230000036039 immunity Effects 0.000 description 6
238000003018 immunoassay Methods 0.000 description 6
210000004962 mammalian cell Anatomy 0.000 description 6
238000010186 staining Methods 0.000 description 6
230000002103 transcriptional effect Effects 0.000 description 6
238000013519 translation Methods 0.000 description 6
230000003612 virological effect Effects 0.000 description 6
230000003442 weekly effect Effects 0.000 description 6
241000699666 Mus <mouse, genus> Species 0.000 description 5
241000711798 Rabies lyssavirus Species 0.000 description 5
238000003556 assay Methods 0.000 description 5
238000006243 chemical reaction Methods 0.000 description 5
238000005520 cutting process Methods 0.000 description 5
230000034994 death Effects 0.000 description 5
231100000517 death Toxicity 0.000 description 5
239000000499 gel Substances 0.000 description 5
230000003053 immunization Effects 0.000 description 5
239000002054 inoculum Substances 0.000 description 5
238000002360 preparation method Methods 0.000 description 5
239000000523 sample Substances 0.000 description 5
230000014621 translational initiation Effects 0.000 description 5
OPIFSICVWOWJMJ-AEOCFKNESA-N 5-bromo-4-chloro-3-indolyl beta-D-galactoside Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=CNC2=CC=C(Br)C(Cl)=C12 OPIFSICVWOWJMJ-AEOCFKNESA-N 0.000 description 4
108020004705 Codon Proteins 0.000 description 4
241000238631 Hexapoda Species 0.000 description 4
241000286209 Phasianidae Species 0.000 description 4
102000045595 Phosphoprotein Phosphatases Human genes 0.000 description 4
108700019535 Phosphoprotein Phosphatases Proteins 0.000 description 4
238000004113 cell culture Methods 0.000 description 4
239000013592 cell lysate Substances 0.000 description 4
201000010099 disease Diseases 0.000 description 4
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
230000000694 effects Effects 0.000 description 4
210000002257 embryonic structure Anatomy 0.000 description 4
238000002649 immunization Methods 0.000 description 4
230000001506 immunosuppresive effect Effects 0.000 description 4
230000000977 initiatory effect Effects 0.000 description 4
239000003550 marker Substances 0.000 description 4
239000012528 membrane Substances 0.000 description 4
229920001184 polypeptide Polymers 0.000 description 4
108090000765 processed proteins & peptides Proteins 0.000 description 4
102000004196 processed proteins & peptides Human genes 0.000 description 4
238000000746 purification Methods 0.000 description 4
108091008146 restriction endonucleases Proteins 0.000 description 4
238000006467 substitution reaction Methods 0.000 description 4
238000013518 transcription Methods 0.000 description 4
230000035897 transcription Effects 0.000 description 4
108091003079 Bovine Serum Albumin Proteins 0.000 description 3
101100333573 Bovine leukemia virus env gene Proteins 0.000 description 3
230000004543 DNA replication Effects 0.000 description 3
201000004624 Dermatitis Diseases 0.000 description 3
238000012286 ELISA Assay Methods 0.000 description 3
101150039660 HA gene Proteins 0.000 description 3
241000700721 Hepatitis B virus Species 0.000 description 3
238000012300 Sequence Analysis Methods 0.000 description 3
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
230000003321 amplification Effects 0.000 description 3
208000010668 atopic eczema Diseases 0.000 description 3
230000015572 biosynthetic process Effects 0.000 description 3
210000003837 chick embryo Anatomy 0.000 description 3
230000000120 cytopathologic effect Effects 0.000 description 3
235000013601 eggs Nutrition 0.000 description 3
239000012091 fetal bovine serum Substances 0.000 description 3
210000002950 fibroblast Anatomy 0.000 description 3
230000008014 freezing Effects 0.000 description 3
238000007710 freezing Methods 0.000 description 3
101150036031 gD gene Proteins 0.000 description 3
238000001114 immunoprecipitation Methods 0.000 description 3
238000011065 in-situ storage Methods 0.000 description 3
238000013507 mapping Methods 0.000 description 3
238000003199 nucleic acid amplification method Methods 0.000 description 3
210000002729 polyribosome Anatomy 0.000 description 3
239000002243 precursor Substances 0.000 description 3
230000009467 reduction Effects 0.000 description 3
239000002356 single layer Substances 0.000 description 3
238000010561 standard procedure Methods 0.000 description 3
238000007920 subcutaneous administration Methods 0.000 description 3
230000004083 survival effect Effects 0.000 description 3
238000010257 thawing Methods 0.000 description 3
210000001519 tissue Anatomy 0.000 description 3
238000004448 titration Methods 0.000 description 3
241000700570 unidentified entomopoxvirus Species 0.000 description 3
101150110188 30 gene Proteins 0.000 description 2
208000030507 AIDS Diseases 0.000 description 2
241000283707 Capra Species 0.000 description 2
241000282693 Cercopithecidae Species 0.000 description 2
206010011703 Cyanosis Diseases 0.000 description 2
102100027723 Endogenous retrovirus group K member 6 Rec protein Human genes 0.000 description 2
101710121417 Envelope glycoprotein Proteins 0.000 description 2
108091029865 Exogenous DNA Proteins 0.000 description 2
208000032843 Hemorrhage Diseases 0.000 description 2
241000282412 Homo Species 0.000 description 2
241000255777 Lepidoptera Species 0.000 description 2
241000721703 Lymantria dispar Species 0.000 description 2
101150118742 NP gene Proteins 0.000 description 2
206010033799 Paralysis Diseases 0.000 description 2
101710182846 Polyhedrin Proteins 0.000 description 2
241000700159 Rattus Species 0.000 description 2
108020004511 Recombinant DNA Proteins 0.000 description 2
238000002105 Southern blotting Methods 0.000 description 2
101150003725 TK gene Proteins 0.000 description 2
241000700647 Variola virus Species 0.000 description 2
208000036142 Viral infection Diseases 0.000 description 2
150000001413 amino acids Chemical class 0.000 description 2
VEZXCJBBBCKRPI-UHFFFAOYSA-N beta-propiolactone Chemical compound O=C1CCO1 VEZXCJBBBCKRPI-UHFFFAOYSA-N 0.000 description 2
230000033228 biological regulation Effects 0.000 description 2
238000003776 cleavage reaction Methods 0.000 description 2
230000000295 complement effect Effects 0.000 description 2
235000021186 dishes Nutrition 0.000 description 2
230000004927 fusion Effects 0.000 description 2
230000012010 growth Effects 0.000 description 2
238000010166 immunofluorescence Methods 0.000 description 2
230000005847 immunogenicity Effects 0.000 description 2
230000001771 impaired effect Effects 0.000 description 2
238000001727 in vivo Methods 0.000 description 2
238000005304 joining Methods 0.000 description 2
210000003292 kidney cell Anatomy 0.000 description 2
210000002414 leg Anatomy 0.000 description 2
239000000463 material Substances 0.000 description 2
238000002703 mutagenesis Methods 0.000 description 2
231100000350 mutagenesis Toxicity 0.000 description 2
238000006386 neutralization reaction Methods 0.000 description 2
230000003472 neutralizing effect Effects 0.000 description 2
102000039446 nucleic acids Human genes 0.000 description 2
108020004707 nucleic acids Proteins 0.000 description 2
150000007523 nucleic acids Chemical class 0.000 description 2
229920002401 polyacrylamide Polymers 0.000 description 2
244000144977 poultry Species 0.000 description 2
235000013594 poultry meat Nutrition 0.000 description 2
229960000380 propiolactone Drugs 0.000 description 2
230000001681 protective effect Effects 0.000 description 2
238000011084 recovery Methods 0.000 description 2
230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 2
230000001105 regulatory effect Effects 0.000 description 2
210000001995 reticulocyte Anatomy 0.000 description 2
230000007017 scission Effects 0.000 description 2
239000011780 sodium chloride Substances 0.000 description 2
230000008961 swelling Effects 0.000 description 2
238000003786 synthesis reaction Methods 0.000 description 2
238000001890 transfection Methods 0.000 description 2
230000009385 viral infection Effects 0.000 description 2
239000005723 virus inoculator Substances 0.000 description 2
239000007762 w/o emulsion Substances 0.000 description 2
JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
102000002260 Alkaline Phosphatase Human genes 0.000 description 1
108020004774 Alkaline Phosphatase Proteins 0.000 description 1
235000006576 Althaea officinalis Nutrition 0.000 description 1
241000670670 Amsacta Species 0.000 description 1
IJYZHIOOBGIINM-WDSKDSINSA-N Arg-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@@H](N)CCCN=C(N)N IJYZHIOOBGIINM-WDSKDSINSA-N 0.000 description 1
241001203868 Autographa californica Species 0.000 description 1
241000894006 Bacteria Species 0.000 description 1
102100021935 C-C motif chemokine 26 Human genes 0.000 description 1
UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
201000006082 Chickenpox Diseases 0.000 description 1
108020004638 Circular DNA Proteins 0.000 description 1
241000254173 Coleoptera Species 0.000 description 1
241000272201 Columbiformes Species 0.000 description 1
UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 1
241000701832 Enterobacteria phage T3 Species 0.000 description 1
241000700572 Entomopoxvirinae Species 0.000 description 1
241000567413 Estigmene Species 0.000 description 1
241000282324 Felis Species 0.000 description 1
206010069540 Generalised vaccinia Diseases 0.000 description 1
108700039691 Genetic Promoter Regions Proteins 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
108060003393 Granulin Proteins 0.000 description 1
101000897493 Homo sapiens C-C motif chemokine 26 Proteins 0.000 description 1
241000700588 Human alphaherpesvirus 1 Species 0.000 description 1
206010062016 Immunosuppression Diseases 0.000 description 1
HHSJMSCOLJVTCX-ZDLURKLDSA-N L-Glutaminyl-L-threonine Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@@H](N)CCC(N)=O HHSJMSCOLJVTCX-ZDLURKLDSA-N 0.000 description 1
125000003798 L-tyrosyl group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C([H])([H])C1=C([H])C([H])=C(O[H])C([H])=C1[H] 0.000 description 1
208000012266 Needlestick injury Diseases 0.000 description 1
206010028980 Neoplasm Diseases 0.000 description 1
239000000020 Nitrocellulose Substances 0.000 description 1
101710163270 Nuclease Proteins 0.000 description 1
241000238814 Orthoptera Species 0.000 description 1
241000287127 Passeridae Species 0.000 description 1
208000027954 Poultry disease Diseases 0.000 description 1
206010037888 Rash pustular Diseases 0.000 description 1
101000702488 Rattus norvegicus High affinity cationic amino acid transporter 1 Proteins 0.000 description 1
241000220317 Rosa Species 0.000 description 1
206010039509 Scab Diseases 0.000 description 1
241000287231 Serinus Species 0.000 description 1
241000287219 Serinus canaria Species 0.000 description 1
241000287181 Sturnus vulgaris Species 0.000 description 1
101800001271 Surface protein Proteins 0.000 description 1
108010008038 Synthetic Vaccines Proteins 0.000 description 1
108091023040 Transcription factor Proteins 0.000 description 1
102000040945 Transcription factor Human genes 0.000 description 1
206010046980 Varicella Diseases 0.000 description 1
108700005077 Viral Genes Proteins 0.000 description 1
238000002835 absorbance Methods 0.000 description 1
208000002552 acute disseminated encephalomyelitis Diseases 0.000 description 1
239000002671 adjuvant Substances 0.000 description 1
239000011543 agarose gel Substances 0.000 description 1
238000000246 agarose gel electrophoresis Methods 0.000 description 1
238000000137 annealing Methods 0.000 description 1
230000005875 antibody response Effects 0.000 description 1
230000002238 attenuated effect Effects 0.000 description 1
230000005540 biological transmission Effects 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
239000008280 blood Substances 0.000 description 1
239000000872 buffer Substances 0.000 description 1
238000010804 cDNA synthesis Methods 0.000 description 1
239000001110 calcium chloride Substances 0.000 description 1
229910001628 calcium chloride Inorganic materials 0.000 description 1
244000309466 calf Species 0.000 description 1
201000011510 cancer Diseases 0.000 description 1
239000013553 cell monolayer Substances 0.000 description 1
230000001413 cellular effect Effects 0.000 description 1
238000005119 centrifugation Methods 0.000 description 1
238000002512 chemotherapy Methods 0.000 description 1
230000002759 chromosomal effect Effects 0.000 description 1
230000000052 comparative effect Effects 0.000 description 1
230000002860 competitive effect Effects 0.000 description 1
239000000356 contaminant Substances 0.000 description 1
229940028617 conventional vaccine Drugs 0.000 description 1
NKLPQNGYXWVELD-UHFFFAOYSA-M coomassie brilliant blue Chemical compound [Na+].C1=CC(OCC)=CC=C1NC1=CC=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C=CC(=CC=2)N(CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=C1 NKLPQNGYXWVELD-UHFFFAOYSA-M 0.000 description 1
210000000805 cytoplasm Anatomy 0.000 description 1
230000001086 cytosolic effect Effects 0.000 description 1
231100000433 cytotoxic Toxicity 0.000 description 1
230000001472 cytotoxic effect Effects 0.000 description 1
230000006735 deficit Effects 0.000 description 1
239000008121 dextrose Substances 0.000 description 1
230000004064 dysfunction Effects 0.000 description 1
238000005516 engineering process Methods 0.000 description 1
230000008029 eradication Effects 0.000 description 1
230000001605 fetal effect Effects 0.000 description 1
239000012530 fluid Substances 0.000 description 1
239000007850 fluorescent dye Substances 0.000 description 1
230000036449 good health Effects 0.000 description 1
230000012447 hatching Effects 0.000 description 1
210000000087 hemolymph Anatomy 0.000 description 1
108010077284 hepatitis B surface antigen presurface protein 2 Proteins 0.000 description 1
230000001900 immune effect Effects 0.000 description 1
210000000987 immune system Anatomy 0.000 description 1
230000016784 immunoglobulin production Effects 0.000 description 1
238000007901 in situ hybridization Methods 0.000 description 1
229940031551 inactivated vaccine Drugs 0.000 description 1
238000010348 incorporation Methods 0.000 description 1
125000001041 indolyl group Chemical group 0.000 description 1
230000008595 infiltration Effects 0.000 description 1
238000001764 infiltration Methods 0.000 description 1
229960003971 influenza vaccine Drugs 0.000 description 1
239000003112 inhibitor Substances 0.000 description 1
230000005764 inhibitory process Effects 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
239000000543 intermediate Substances 0.000 description 1
238000002955 isolation Methods 0.000 description 1
240000001854 junco Species 0.000 description 1
238000011005 laboratory method Methods 0.000 description 1
230000002045 lasting effect Effects 0.000 description 1
244000144972 livestock Species 0.000 description 1
230000004807 localization Effects 0.000 description 1
210000005265 lung cell Anatomy 0.000 description 1
210000001161 mammalian embryo Anatomy 0.000 description 1
239000000203 mixture Substances 0.000 description 1
238000012986 modification Methods 0.000 description 1
230000004048 modification Effects 0.000 description 1
238000010369 molecular cloning Methods 0.000 description 1
210000003205 muscle Anatomy 0.000 description 1
210000004237 neck muscle Anatomy 0.000 description 1
239000013642 negative control Substances 0.000 description 1
229920001220 nitrocellulos Polymers 0.000 description 1
238000007899 nucleic acid hybridization Methods 0.000 description 1
239000013600 plasmid vector Substances 0.000 description 1
208000029561 pustule Diseases 0.000 description 1
229940124551 recombinant vaccine Drugs 0.000 description 1
238000011160 research Methods 0.000 description 1
238000012770 revaccination Methods 0.000 description 1
238000011076 safety test Methods 0.000 description 1
210000003079 salivary gland Anatomy 0.000 description 1
230000018040 scab formation Effects 0.000 description 1
238000007790 scraping Methods 0.000 description 1
238000000926 separation method Methods 0.000 description 1
238000013207 serial dilution Methods 0.000 description 1
238000002741 site-directed mutagenesis Methods 0.000 description 1
208000017520 skin disease Diseases 0.000 description 1
238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
230000007480 spreading Effects 0.000 description 1
238000003892 spreading Methods 0.000 description 1
239000000758 substrate Substances 0.000 description 1
239000000725 suspension Substances 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
208000011580 syndromic disease Diseases 0.000 description 1
230000002123 temporal effect Effects 0.000 description 1
210000000966 temporal muscle Anatomy 0.000 description 1
230000001256 tonic effect Effects 0.000 description 1
230000010474 transient expression Effects 0.000 description 1
239000003656 tris buffered saline Substances 0.000 description 1
210000000689 upper leg Anatomy 0.000 description 1
230000029812 viral genome replication Effects 0.000 description 1
230000017613 viral reproduction Effects 0.000 description 1
230000006490 viral transcription Effects 0.000 description 1
239000013603 viral vector Substances 0.000 description 1
238000012800 visualization Methods 0.000 description 1
238000005406 washing Methods 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
- C12N2710/16622—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24041—Use of virus, viral particle or viral elements as a vector
- C12N2710/24043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
- C12N2760/18122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/20011—Rhabdoviridae
- C12N2760/20111—Lyssavirus, e.g. rabies virus
- C12N2760/20122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Virology (AREA)
Genetics & Genomics (AREA)
General Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Medicinal Chemistry (AREA)
Molecular Biology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Chemical & Material Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Chemical Kinetics & Catalysis (AREA)
Biotechnology (AREA)
Oncology (AREA)
Biomedical Technology (AREA)
Wood Science & Technology (AREA)
Biochemistry (AREA)
Zoology (AREA)
Biophysics (AREA)
General Engineering & Computer Science (AREA)
Communicable Diseases (AREA)
Bioinformatics & Cheminformatics (AREA)
Microbiology (AREA)
Plant Pathology (AREA)
Hematology (AREA)
Physics & Mathematics (AREA)
Gastroenterology & Hepatology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)

AU24275/88A 1987-08-28 1988-08-24 Recombinant avipox virus Abandoned AU2427588A (en)

Applications Claiming Priority (8)

Application Number	Priority Date	Filing Date
US9071187A	1987-08-28	1987-08-28
US090711		1987-08-28
US11033587A	1987-10-20	1987-10-20
US110335		1987-10-20
US18605488A	1988-04-25	1988-04-25
US186054		1988-04-25
US23439088A	1988-08-23	1988-08-23
US234390		1988-08-23

Related Child Applications (1)

Application Number	Title	Priority Date	Filing Date
AU16288/95A Division AU690210B2 (en)	1987-08-28	1995-04-05	Recombinant virus

Publications (1)

Publication Number	Publication Date
AU2427588A true AU2427588A (en)	1989-05-02

Family

ID=27492413

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
AU24275/88A Abandoned AU2427588A (en)	1987-08-28	1988-08-24	Recombinant avipox virus
AU16288/95A Expired AU690210B2 (en)	1987-08-28	1995-04-05	Recombinant virus

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
AU16288/95A Expired AU690210B2 (en)	1987-08-28	1995-04-05	Recombinant virus

Country Status (17)

Country	Link
JP (3)	JP3348156B2 (ja)
KR (1)	KR970011149B1 (ja)
AR (1)	AR241939A1 (ja)
AT (1)	AT408549B (ja)
AU (2)	AU2427588A (ja)
BE (1)	BE1002134A5 (ja)
CH (2)	CH679933A5 (ja)
DE (4)	DE10399031I1 (ja)
DK (1)	DK175904B1 (ja)
FR (1)	FR2621487B1 (ja)
GB (1)	GB2217718B (ja)
IL (1)	IL87581A0 (ja)
IT (1)	IT1229484B (ja)
LU (2)	LU90951I2 (ja)
NL (4)	NL195051C (ja)
NZ (1)	NZ225970A (ja)
WO (1)	WO1989003429A1 (ja)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU623913B2 (en) *	1988-06-24	1992-05-28	British Technology Group Limited	Fowlpox virus non-essential regions
AU670538B2 (en) *	1991-07-26	1996-07-25	Virogenetics Corporation	Infectious bursal disease virus recombinant poxvirus vaccine
AU672359B2 (en) *	1991-03-07	1996-10-03	Virogenetics Corporation	Genetically engineered vaccine strain
AU672581B2 (en) *	1991-03-07	1996-10-10	Virogenetics Corporation	Immunodeficiency virus recombinant poxvirus vaccine

Families Citing this family (112)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5338683A (en) *	1981-12-24	1994-08-16	Health Research Incorporated	Vaccinia virus containing DNA sequences encoding herpesvirus glycoproteins
US5505941A (en) *	1981-12-24	1996-04-09	Health Research, Inc.	Recombinant avipox virus and method to induce an immune response
US7045313B1 (en)	1982-11-30	2006-05-16	The United States Of America As Represented By The Department Of Health And Human Services	Recombinant vaccinia virus containing a chimeric gene having foreign DNA flanked by vaccinia regulatory DNA
DE10399031I1 (de) *	1987-08-28	2004-01-29	Health Research Inc	Rekombinante Viren.
US5286639A (en) *	1987-09-16	1994-02-15	Nippon Zeon Co., Ltd.	Recombinant avipoxvirus
DE3813093A1 (de) *	1988-04-19	1989-11-09	Immuno Ag	Rekombinantes plasmid, verfahren zum herstellen eines rekombinanten avipoxvirus, rekombinantes avipoxvirus und dessen verwendung
US5631154A (en) *	1988-06-10	1997-05-20	Therion Biologics, Incorporated	Self assembled, defective, non-self-propagating lentivirus particles
US5093258A (en) *	1988-08-26	1992-03-03	Therion Biologics Corporation	Recombinant fowlpox virus and recombination vector
CA2001001A1 (en) *	1988-10-21	1990-04-21	Matthew M. Binns	Fowlpox virus promoter
US6248333B1 (en)	1990-04-04	2001-06-19	Health Research Inc.	Isolated nucleic acid sequence of equine herpesvirus type 1 glycoprotein D (EHV-1 gD)
US5204243A (en) *	1990-02-14	1993-04-20	Health Research Incorporated	Recombinant poxvirus internal cores
US5514375A (en) *	1990-08-15	1996-05-07	Virogenetics Corporation	Flavivirus recombinant poxvirus vaccine
MY109299A (en) *	1990-08-15	1996-12-31	Virogenetics Corp	Recombinant pox virus encoding flaviviral structural proteins
FR2668064B1 (fr) *	1990-10-23	1994-12-16	Transgene Sa	Composition pharmaceutique pour le traitement ou la prevention d'une tumeur maligne.
US5759841A (en) *	1990-11-20	1998-06-02	Virogenetics Corporation	Immunological composition of measles virus utilizing recombinant poxvirus
US6309647B1 (en)	1999-07-15	2001-10-30	Aventis Pasteur	Poxvirus—canine dispemper virus (CDV) or measles virus recombinants and compositions and methods employing the recombinants
US5503834A (en) *	1990-11-20	1996-04-02	Virogenetics Corporation	Measles virus recombinant poxvirus vaccine
US5756102A (en) *	1990-11-20	1998-05-26	Virogenetics Corporation	Poxvirus-canine distemper virus (CDV) recombinants and compositions and methods employing the recombinants
IE71643B1 (en) *	1990-11-20	1997-02-26	Virogenetics Corp	A recombinant poxviral vaccine for canine distemper
US5338679A (en) *	1991-01-08	1994-08-16	Her Majesty The Queen In Right Of Canada, As Represented By National Research Council Canada And Forestry Canada	Vertebrate poxvoris expression vector under the control of entomopoxvirus spheroidin gene promoter
US5766597A (en) *	1991-03-07	1998-06-16	Virogenetics Corporation	Malaria recombinant poxviruses
US5863542A (en) *	1991-03-07	1999-01-26	Virogenetics Corporation	Recombinant attenuated ALVAC canaryopox virus containing heterologous HIV or SIV inserts
US5756101A (en) *	1991-07-01	1998-05-26	Pasteur Merieux Serums Et Vaccins	Malaria recombinant poxvirus
US5766598A (en) *	1991-03-07	1998-06-16	Virogenetics Corporation	Recombinant attenuated ALVAC canarypoxvirus expression vectors containing heterologous DNA segments encoding lentiviral gene products
AU674491B2 (en) *	1991-03-20	1997-01-02	Virogenetics Corporation	Recombinant poxvirus malaria vaccine
ES2212795T3 (es) *	1991-08-26	2004-08-01	Baxter Healthcare S.A.	Virus de la viruela de las aves de corral recombinante.
US5443831A (en) *	1991-10-29	1995-08-22	University Of Delaware	Gene encoding glycoprotein B of Infectious Laryngotracheitis Virus
US6251403B1 (en)	1992-01-13	2001-06-26	Syntro Corporation	Recombinant swinepox virus
US5869312A (en) *	1992-01-13	1999-02-09	Syntro Corporation	Recombinant swinepox virus
EP0623172B1 (en) *	1992-01-13	2004-12-29	Virogenetics Corporation	Marek's disease virus recombinant vaccinia virus vaccine
US6497882B1 (en)	1992-01-13	2002-12-24	Syntro Corporation	Recombinant swinepox virus
US6328975B1 (en)	1992-01-13	2001-12-11	Syntro Corporation	Recombinant swinepox virus
US6033904A (en) *	1992-01-13	2000-03-07	Syntro Corporation	Recombinant swinepox virus
US6127163A (en) *	1992-01-13	2000-10-03	Syntro Corporation	Recombinant swinepox virus
AU5138293A (en) *	1992-09-21	1994-04-12	Chiron Viagene, Inc.	Recombinant retroviral vector against felv and/or fiv
US5925358A (en) *	1993-02-26	1999-07-20	Syntro Corporation	Recombinant fowlpox viruses and uses thereof
WO1994019015A1 (en) *	1993-02-26	1994-09-01	Syntro Corporation	Recombinant fowlpox viruses and uses thereof
US6136318A (en) *	1993-02-26	2000-10-24	Cochran; Mark D.	Recombinant fowlpox viruses and uses thereof
AU727278B2 (en) *	1993-02-26	2000-12-07	Syntro Corporation	Recombinant fowlpox viruses and uses thereof II
US5496731A (en) *	1993-03-25	1996-03-05	Xu; Hong-Ji	Broad-spectrum tumor suppressor genes, gene products and methods for tumor suppressor gene therapy
US5843742A (en) *	1994-12-16	1998-12-01	Avigen Incorporated	Adeno-associated derived vector systems for gene delivery and integration into target cells
EP0753581A1 (en)	1995-07-10	1997-01-15	Immuno Ag	Improved recombinant eukaryotic cytoplasmic viruses, method for their production and their use as vaccines
US5858373A (en) *	1995-12-01	1999-01-12	Virogenetics Corporation	Recombinant poxvirus-feline infectious peritionitis virus, compositions thereof and methods for making and using them
JP4475683B2 (ja)	1996-07-25	2010-06-09	アメリカ合衆国	腫瘍関連抗原に対する免疫のための組換えポックス・ウイルス
US6106825A (en) *	1997-05-07	2000-08-22	University Of Florida	Entomopoxvirus-vertebrate gene delivery vector and method
AU3910097A (en) *	1997-08-05	1999-03-01	Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The	Live recombinant vaccine comprising inefficiently or non-replicating vir us
US6248582B1 (en) *	1997-10-08	2001-06-19	Imran Khan	Gene deleted recombinant FeLV proviral DNA for production of vaccines against FeLV
JPH11165762A (ja)	1997-12-01	1999-06-22	Lintec Corp	チップ体搬送用カバーテープおよび封止構造体
US20020147143A1 (en)	1998-03-18	2002-10-10	Corixa Corporation	Compositions and methods for the therapy and diagnosis of lung cancer
US20030235557A1 (en)	1998-09-30	2003-12-25	Corixa Corporation	Compositions and methods for WT1 specific immunotherapy
US6200560B1 (en)	1998-10-20	2001-03-13	Avigen, Inc.	Adeno-associated virus vectors for expression of factor VIII by target cells
US6221349B1 (en)	1998-10-20	2001-04-24	Avigen, Inc.	Adeno-associated vectors for expression of factor VIII by target cells
EP1141313A2 (en)	1998-12-31	2001-10-10	Chiron Corporation	Improved expression of hiv polypeptides and production of virus-like particles
US7935805B1 (en)	1998-12-31	2011-05-03	Novartis Vaccines & Diagnostics, Inc	Polynucleotides encoding antigenic HIV Type C polypeptides, polypeptides and uses thereof
AU5773500A (en)	1999-06-28	2001-01-31	Board Of Trustees Of The University Of Illinois, The	Inhibitors of memapsin 2 and use thereof
PL209127B1 (pl)	2000-02-23	2011-07-29	Smithkline Beecham Biolog	Środek farmaceutyczny do stosowania w immunoterapeutycznym leczeniu raka i sposób diagnozowania u pacjenta obecności lub podatności na raka
DE60134158D1 (de)	2000-06-28	2008-07-03	Corixa Corp	Zusammensetzungen und verfahren für therapie und diagnose von lungenkrebs
DE60239317D1 (de)	2001-01-12	2011-04-14	Novartis Vaccines & Diagnostic	Nukleinsäure mukosale immunisierung
DE60209345T2 (de) *	2001-03-08	2006-08-03	Akzo Nobel N.V.	Leporipox-basierende vektorvakzine
JP4499311B2 (ja) *	2001-04-27	2010-07-07	シャープ株式会社	放送受信端末
EP1988097A1 (en)	2001-05-09	2008-11-05	Corixa Corporation	Compositions and methods for the therapy and diagnosis of prostate cancer
EP2280074A3 (en)	2001-07-05	2011-06-22	Novartis Vaccines and Diagnostics, Inc.	Polynucleotides encoding antigenic HIV type B and/or type C polypeptides, polypeptides and uses thereof
JP5033303B2 (ja)	2001-07-05	2012-09-26	ノバルティスバクシンズアンドダイアグノスティックス，インコーポレーテッド	抗原性ｃ型ｈｉｖポリペプチドをコードするポリヌクレオチド、ポリペプチドおよびそれらの使用
ES2405405T3 (es)	2001-12-17	2013-05-31	Corixa Corporation	Composiciones y procedimientos para la terapia y el diagnóstico de enfermedad inflamatoria del intestino
JP4838706B2 (ja)	2003-01-06	2011-12-14	コリクサコーポレイション	所定のアミノアルキルグルコサミニドフォスフェート化合物及びそれらの使用
US7960522B2 (en)	2003-01-06	2011-06-14	Corixa Corporation	Certain aminoalkyl glucosaminide phosphate compounds and their use
CA2525825A1 (en)	2003-05-15	2005-01-27	Chiron Corporation	Hiv polynucleotides and polypeptides derived from botswana mj4
US7261882B2 (en)	2003-06-23	2007-08-28	Reagents Of The University Of Colorado	Methods for treating neuropathic pain by administering IL-10 polypeptides
MX2007003400A (es)	2004-09-22	2008-03-04	Glaxosmithkline Biolog Sa	Composicion inmunogena.
ES2514316T3 (es)	2005-11-22	2014-10-28	Novartis Vaccines And Diagnostics, Inc.	Partículas similares a virus (VLPs) de Norovirus y Sapovirus
AU2007239095B2 (en)	2006-01-09	2012-05-03	The Regents Of The University Of California	Immunostimulatory combinations for vaccine adjuvants
WO2007106536A2 (en)	2006-03-14	2007-09-20	Oregon Health & Science University	Methods for producing an immune response to tuberculosis
EP2125868B1 (en)	2007-02-28	2015-06-10	The Govt. Of U.S.A. As Represented By The Secretary Of The Department Of Health And Human Services	Brachyury polypeptides and methods for use
AU2008314486B2 (en)	2007-10-15	2014-06-26	Jingang Medicine (Australia) Pty Ltd	Construct system and uses therefor
US8691502B2 (en)	2008-10-31	2014-04-08	Tremrx, Inc.	T-cell vaccination with viral vectors via mechanical epidermal disruption
EP2384120B1 (en)	2009-01-05	2019-12-11	Epitogenesis Inc.	Adjuvant compositions and methods of use
WO2010099472A2 (en)	2009-02-27	2010-09-02	The U.S.A. Of America, As Represented By The Secretary, Department Of Health And Human Services	Spanx-b polypeptides and their use
EP3263124A1 (en)	2009-11-20	2018-01-03	Oregon Health&Science University	Methods for producing an immune response to tuberculosis
US20130052221A1 (en)	2010-02-26	2013-02-28	The Govt. of the U.S, as represented by The Sec. of The Dept. of Health and Human Services	Dna-protein vaccination protocols
US9795658B2 (en)	2010-04-20	2017-10-24	Admedus Vaccines Pty Ltd	Expression system for modulating an immune response
EP2670426B1 (en)	2011-01-31	2017-05-10	The General Hospital Corporation	Multimodal trail molecules and uses in cellular therapies
WO2012151272A2 (en)	2011-05-02	2012-11-08	Tremrx, Inc.	T-cell vaccination with viral vectors via mechanical epidermal disruption
WO2012177595A1 (en)	2011-06-21	2012-12-27	Oncofactor Corporation	Compositions and methods for the therapy and diagnosis of cancer
WO2012178118A1 (en)	2011-06-24	2012-12-27	Epitogenesis Inc.	Pharmaceutical compositions, comprising a combination of select carriers, vitamins, tannins and flavonoids as antigen-specific immuno-modulators
US20150004144A1 (en)	2011-12-02	2015-01-01	The General Hospital Corporation	Differentiation into brown adipocytes
US9605074B2 (en)	2012-08-30	2017-03-28	The General Hospital Corporation	Multifunctional nanobodies for treating cancer
US20150224181A1 (en)	2012-09-14	2015-08-13	The United States Of America As Represented By The Secretary Department Of Health And Human Se	Brachyury protein, non-poxvirus non-yeast vectors encoding brachyury protein, and their use
WO2014043535A1 (en)	2012-09-14	2014-03-20	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Compositions for the treatment of cancer
SG10201708547YA (en)	2013-04-17	2017-11-29	Genzyme Corp	Compositions and methods for treating and preventing macular degeneration
CA2913155A1 (en)	2013-05-21	2014-11-27	President And Fellows Of Harvard College	Engineered heme-binding compositions and uses thereof
CA2930693A1 (en)	2013-11-15	2015-05-21	The Board Of Trustees Of The Leland Stanford Junior Unversity	Methods of treating heart failure with agonists of hypocretin receptor 2
AU2015213770A1 (en)	2014-02-06	2016-09-01	Genzyme Corporation	Compositions and methods for treating and preventing macular degeneration
EP3194446B1 (en)	2014-09-18	2022-10-26	Cedars-Sinai Medical Center	Compositions and methods for treating fibrosis
WO2016154010A1 (en)	2015-03-20	2016-09-29	Makidon Paul	Immunogenic compositions for use in vaccination against bordetella
US20180112006A1 (en)	2015-04-17	2018-04-26	The General Hospital Corporation	Agents, systems and methods for treating cancer
WO2016172479A1 (en)	2015-04-22	2016-10-27	Cedars-Sinai Medical Center	Enterically delivered bitter oligopeptides for the treatment for type 2 diabetes
ES2959642T3 (es)	2015-05-13	2024-02-27	The Us Secretary Of The Department Of Health And Human Services	Metodos y composiciones para inducir una respuesta inmunitaria mediante construcciones con elementos conservados
WO2016196366A1 (en)	2015-05-29	2016-12-08	The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services	Extension of replicative lifespan in diseases of premature aging using p53 isoforms
EP3313863B1 (en)	2015-06-29	2020-12-23	The Board of Trustees of the Leland Stanford Junior University	Degron fusion constructs and methods for controlling protein production
JP7110108B2 (ja)	2015-12-09	2022-08-01	ジンガンメディスン（オーストラリア）プロプライアタリーリミティド	治療用免疫調節組成物
WO2018018082A1 (en)	2016-07-26	2018-02-01	The Australian National University	Immunostimulatory compositions and uses therefor
US10917454B1 (en)	2019-08-01	2021-02-09	Rohde & Schwarz Gmbh & Co. Kg	System and method for ATC voice quality assurance
WO2023070072A1 (en)	2021-10-21	2023-04-27	The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone	Retroelement-generated transcription factor decoys
WO2023077147A2 (en)	2021-11-01	2023-05-04	Pellis Therapeutics, Inc.	T-cell vaccines for patients with reduced humoral immunity
CA3237482A1 (en)	2021-11-03	2023-05-11	The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone	Precise genome editing using retrons
WO2023141602A2 (en)	2022-01-21	2023-07-27	Renagade Therapeutics Management Inc.	Engineered retrons and methods of use
WO2023183589A1 (en)	2022-03-25	2023-09-28	The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone	Rt-dna fidelity and retron genome editing
WO2023183627A1 (en)	2022-03-25	2023-09-28	The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone	Production of reverse transcribed dna (rt-dna) using a retron reverse transcriptase from exogenous rna
WO2023183588A1 (en)	2022-03-25	2023-09-28	The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone	Methods of assessing engineered retron activity, and uses thereof
WO2024020346A2 (en)	2022-07-18	2024-01-25	Renagade Therapeutics Management Inc.	Gene editing components, systems, and methods of use
WO2024044673A1 (en)	2022-08-24	2024-02-29	The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone	Dual cut retron editors for genomic insertions and deletions
WO2024044723A1 (en)	2022-08-25	2024-02-29	Renagade Therapeutics Management Inc.	Engineered retrons and methods of use

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DK489481A (da) *	1980-11-10	1982-05-11	Searle & Co	Plasmidvektor og frmgangsmaade til fremstilling deraf
US4603112A (en) *	1981-12-24	1986-07-29	Health Research, Incorporated	Modified vaccinia virus
AU570940B2 (en) *	1982-11-30	1988-03-31	United States of America, as represented by the Secretary, U.S. Department of Commerce, The	Process for producing poxvirus recombinants for expression offoreign genes
FR2563434B1 (fr) *	1984-04-25	1986-07-25	Transgene Sa	Vaccin contre la rage et procede pour sa preparation
EP0190254A4 (en) *	1984-07-05	1987-03-09	Genex Corp	GENE CLONE AND PROCESS FOR THE PREPARATION AND USE THEREOF.
DD235669A1 (de) *	1985-03-26	1986-05-14	Akad Wissenschaften Ddr	Verfahren zur herstellung eines blv-kodierten huellproteins
US5032520A (en) *	1985-03-29	1991-07-16	National Research Development Corporation	DNA sequences encoding infectious bronchitis virus spike protein
AU6170486A (en) *	1985-08-23	1987-02-26	Advanced Genetics Research Institute	Defective viral vaccines
AU607399B2 (en) *	1985-09-09	1991-03-07	Cetus Corporation	Infectious recombinant virus vaccine for feline leukemia
NZ217645A (en) *	1985-09-25	1991-11-26	Oncogen	Recombinant viruses expressing lav/htlv-iii related epitopes and vaccine formulations
AU602875B2 (en) *	1985-12-18	1990-11-01	British Technology Group Limited	Newcastle disease virus gene clones
WO1988002022A1 (en) *	1986-09-22	1988-03-24	Commonwealth Scientific And Industrial Research Or	Recombinant poxviruses
AU8075787A (en) *	1986-09-22	1988-04-07	Australian National University, The	Recombinant poxviruses
EP0261940A3 (en) *	1986-09-23	1989-07-05	Applied Biotechnology, Inc.	Pseudorabies vaccines and dna vectors for recombination with pox viruses
EP0284416B1 (en) *	1987-03-27	1995-02-22	Nippon Zeon Co., Ltd.	Recombinant avipoxyvirus
DE10399031I1 (de) *	1987-08-28	2004-01-29	Health Research Inc	Rekombinante Viren.
GB8724885D0 (en) *	1987-10-23	1987-11-25	Binns M M	Fowlpox virus promotors
FR2632863B2 (fr) *	1987-10-29	1990-08-31	Transgene Sa	Virus du fowlpox recombinant et vaccins derives de ces virus
DE68912441T2 (de) *	1988-06-24	1994-05-11	British Tech Group	Nichtessentielle Geflügelpockenvirus-Regionen.
AU625584B2 (en) *	1989-03-08	1992-07-16	Health Research Inc.	Recombinant poxvirus host selection system
EP0550553B1 (en) *	1990-09-25	2000-07-12	Cantab Pharmaceuticals Research Limited	Viral defective vaccine produced by transcomplementing cell line

1987
- 1987-08-24 DE DE2003199031 patent/DE10399031I1/de active Pending
- 1987-08-24 DE DE2003199032 patent/DE10399032I1/de active Pending
1988
- 1988-08-24 CH CH1652/89A patent/CH679933A5/de not_active IP Right Cessation
- 1988-08-24 GB GB8908921A patent/GB2217718B/en not_active Expired - Lifetime
- 1988-08-24 WO PCT/US1988/002816 patent/WO1989003429A1/en active Application Filing
- 1988-08-24 DE DE3890874A patent/DE3890874C5/de not_active Expired - Lifetime
- 1988-08-24 JP JP50771588A patent/JP3348156B2/ja not_active Expired - Lifetime
- 1988-08-24 KR KR1019890700753A patent/KR970011149B1/ko not_active IP Right Cessation
- 1988-08-24 AT AT0900788A patent/AT408549B/de not_active IP Right Cessation
- 1988-08-24 AU AU24275/88A patent/AU2427588A/en not_active Abandoned
- 1988-08-24 CH CH1444/91A patent/CH679934A5/de not_active IP Right Cessation
- 1988-08-24 DE DE2002199049 patent/DE10299049I1/de active Pending
- 1988-08-24 NL NL8820679A patent/NL195051C/nl not_active IP Right Cessation
- 1988-08-28 IL IL87581A patent/IL87581A0/xx not_active IP Right Cessation
- 1988-08-29 IT IT8821772A patent/IT1229484B/it active
- 1988-08-29 NZ NZ225970A patent/NZ225970A/xx unknown
- 1988-08-29 FR FR888811334A patent/FR2621487B1/fr not_active Expired - Lifetime
- 1988-08-29 AR AR88311787A patent/AR241939A1/es active
- 1988-08-29 BE BE8800978A patent/BE1002134A5/fr not_active IP Right Cessation
1989
- 1989-04-27 DK DK198902036A patent/DK175904B1/da active Protection Beyond IP Right Term
1995
- 1995-04-05 AU AU16288/95A patent/AU690210B2/en not_active Expired
2001
- 2001-10-09 JP JP2001311076A patent/JP2002186494A/ja active Pending
2002
- 2002-03-15 JP JP2002071416A patent/JP3826055B2/ja not_active Expired - Lifetime
- 2002-09-04 LU LU90951C patent/LU90951I2/fr unknown
2003
- 2003-07-09 NL NL300130C patent/NL300130I2/nl unknown
- 2003-09-05 LU LU91039C patent/LU91039I2/fr unknown
- 2003-11-25 NL NL300138C patent/NL300138I2/nl unknown
- 2003-11-25 NL NL300139C patent/NL300139I1/nl unknown

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU623913B2 (en) *	1988-06-24	1992-05-28	British Technology Group Limited	Fowlpox virus non-essential regions
AU672359B2 (en) *	1991-03-07	1996-10-03	Virogenetics Corporation	Genetically engineered vaccine strain
AU672581B2 (en) *	1991-03-07	1996-10-10	Virogenetics Corporation	Immunodeficiency virus recombinant poxvirus vaccine
AU670538B2 (en) *	1991-07-26	1996-07-25	Virogenetics Corporation	Infectious bursal disease virus recombinant poxvirus vaccine

Also Published As

Publication number	Publication date
AU690210B2 (en)	1998-04-23
NL300139I1 (nl)	2004-02-02
NL300138I1 (nl)	2004-02-02
GB8908921D0 (en)	1989-08-02
DE10399031I1 (de)	2004-01-29
JP3348156B2 (ja)	2002-11-20
JP3826055B2 (ja)	2006-09-27
AT408549B (de)	2001-12-27
GB2217718A (en)	1989-11-01
AU1628895A (en)	1995-08-17
LU90951I2 (fr)	2003-01-15
IT8821772A0 (it)	1988-08-29
IL87581A0 (en)	1989-01-31
DK203689A (da)	1989-06-27
CH679934A5 (ja)	1992-05-15
JP2002186494A (ja)	2002-07-02
FR2621487A1 (fr)	1989-04-14
KR890701757A (ko)	1989-12-21
DK175904B1 (da)	2005-06-06
NL300138I2 (nl)	2004-03-01
WO1989003429A1 (en)	1989-04-20
NL300130I2 (nl)	2005-11-01
LU91039I2 (fr)	2003-11-05
DE10299049I1 (de)	2004-07-01
NZ225970A (en)	1991-01-29
JPH02500879A (ja)	1990-03-29
BE1002134A5 (fr)	1990-07-24
DE3890874C5 (de)	2005-10-20
CH679933A5 (ja)	1992-05-15
DE3890874C2 (de)	2003-03-13
GB2217718B (en)	1992-05-20
JP2002348255A (ja)	2002-12-04
AR241939A1 (es)	1993-01-29
DK203689D0 (da)	1989-04-27
DE10399032I1 (de)	2004-01-29
FR2621487B1 (fr)	1991-10-18
KR970011149B1 (ko)	1997-07-07
ATA900788A (de)	1995-05-15
NL8820679A (nl)	1989-07-03
NL300130I1 (nl)	2003-09-01
IT1229484B (it)	1991-09-03
NL195051C (nl)	2003-07-01

Publication	Publication Date	Title
US6340462B1 (en)	2002-01-22	Recombinant avipox virus
US5174993A (en)	1992-12-29	Recombinant avipox virus and immunological use thereof
AU690210B2 (en)	1998-04-23	Recombinant virus
US5225336A (en)	1993-07-06	Recombinant poxvirus host range selection system
US5453364A (en)	1995-09-26	Recombinant poxvirus host range selection system
US7144578B2 (en)	2006-12-05	Poxvirus-rabies recombinants and compositions and methods employing the recombinants
JP2002514885A (ja)	2002-05-21	ポックスウイルス−イヌジステンパーウイルス（ｃｄｖ）組み換え体類および組成物類および前記組み換え体類を用いる方法
IT9020063A1 (it)	1991-10-17	Vaccino di poxvirus ricombinante di herpesvirus
JP2007082551A (ja)	2007-04-05	組換えポックスウイルス−カリシウイルス［ウサギ出血疾患ウイルス（ｒｈｄｖ）］組成物および使用
JP2007254489A (ja)	2007-10-04	Ｈｔｌｖ抗原を発現する組換え弱毒化ポックスウイルスを含有する免疫原性組成物
US5858373A (en)	1999-01-12	Recombinant poxvirus-feline infectious peritionitis virus, compositions thereof and methods for making and using them
WO1996039177A9 (en)	1997-01-30	Recombinant poxvirus-calicivirus [rabbit hemorrhagic disease virus (rhdv)] compositions and uses
WO2007115385A2 (en)	2007-10-18	Transfer plasmidic vector and recombinant canarypox virus
AU761321B2 (en)	2003-06-05	Recombinant viruses, vaccines containing them and in vitro cell cultures thereof
AU725985B2 (en)	2000-10-26	Recombinant virus
CA1341403C (en)	2002-11-26	Recombinant a vipox virus
DK175980B1 (da)	2005-10-24	Recombinante vacciniavira og anvendelsen af samme
DK176068B1 (da)	2006-03-06	Rekombinant kanaripoxvirus og anvendelsen af samme
DK176165B1 (da)	2006-11-06	Rekombinant fjerkræpoxvirus samt anvendelsen af samme
IE60309B1 (en)	1994-06-29	Recombinant viruses, vaccines containing them and in vitro cell cultures thereof
AU6247000A (en)	2000-12-14	Recombinant poxvirus-calicivirus (rabbit hemorrhagic disease virus (RHDV)) compositions and uses

AU2427588A - Recombinant avipox virus - Google Patents

Info

Links

Classifications

Landscapes

Applications Claiming Priority (8)

Related Child Applications (1)

Publications (1)

Family

ID=27492413

Family Applications (2)

Family Applications After (1)

Country Status (17)

Cited By (4)

Families Citing this family (112)

Family Cites Families (21)

Cited By (4)

Also Published As

Similar Documents